Markets move fast. You should move faster. Be the first to know when deals break, stocks move, or biotech headlines hit. Sign up to get breaking news alerts the moment they happen.
Joby, Archer, and Beta stocks surge after DOT selects them for Trump's eVTOL air taxi pilot program — electric flying taxis set to test in 26 states starting summer 2026.
Vertex Pharmaceuticals' povetacicept succeeds in Phase 3 RAINIER trial for IgA nephropathy with 52% proteinuria reduction. Positive safety data and FDA submission planned soon.
HPE reported strong Q1 2026 results with $9.3B revenue (+18% YoY) and Networking revenue soaring 151%. Beat EPS estimates and raised full-year guidance on robust AI demand.
Trevi Therapeutics shares plunged despite positive FDA alignment for Haduvio in IPF chronic cough. Plans for two Phase 3 trials (instead of one) triggered sell-off; Stifel holds Buy rating on the de-risked program.
Relmada shares jumped sharply after positive 12-month Phase 2 trial data for NDV-01 in bladder cancer and announcement of $160M financing to advance development.
H.C. Wainwright calls Roche’s persevERA trial disappointing but says it’s not a full readthrough for Olema Oncology. Different CDK4/6 inhibitor (ribociclib) may favor palazestrant in OPERA-02.
